Warning Letter — Texinkart Inc.
The FDA issued a warning letter to Texinkart Inc. following an investigation by the Center for Drug Evaluation and Research (CDER).
This notice affects Texinkart Inc., along with regulatory and quality assurance departments responsible for drug product compliance and marketing authorizations.
The issuance of a warning letter by CDER typically indicates significant deviations from the Federal Food, Drug, and Cosmetic Act, often involving the distribution of unapproved new drugs or misbranding. While the specific violations are not detailed in the provided excerpt, such actions usually necessitate immediate corrective measures to avoid further enforcement, such as seizure or injunction.
Regulatory and compliance teams should verify that all product listings and marketing claims are supported by appropriate FDA filings. Internal audits should focus on ensuring that products intended for therapeutic use are not being distributed without necessary drug approvals.
FDA Warning Letter issued to: Texinkart Inc.. 06/17/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/texinkart-inc-729046-06172026
Open in openFDA / FDA.gov